Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.32 |
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881592 | 1.00 | TMPRSS2 (0.36) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL17719239 | 0.95 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL30002783 | 0.95 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL17761548 | 0.95 | TMPRSS2 (0.41) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL23813344 | 0.93 | TMPRSS2 (0.37) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL26002364 | 0.91 | TMPRSS2 (0.38) | TMPRSS2CYP3A4CYP2C9RIPK1POLRMT | |
| SCHEMBL881479 | 0.90 | TMPRSS2 (0.36) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL31571361 | 0.89 | TMPRSS2 (0.43) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL22342697 | 0.89 | TMPRSS2 (0.43) | TMPRSS2CYP3A4CYP2C9RIPK1 | |
| SCHEMBL17712264 | 0.89 | TMPRSS2 (0.43) | TMPRSS2CYP3A4CYP2C9RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | TMPRSS2 12/4885CYP3A4 1145/4885CYP2C9 2167/4885 |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | TMPRSS2 12/4885CYP3A4 1145/4885CYP2C9 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.